Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review
Research output: Contribution to journal/Conference contribution in journal/Contribution to newspaper › Journal article › Research › peer-review
}
TY - JOUR
T1 - Regorafenib Efficacy After Sorafenib in Patients With Recurrent Hepatocellular Carcinoma After Liver Transplantation
T2 - A Retrospective Study
AU - Iavarone, Massimo
AU - Invernizzi, Federica
AU - Ivanics, Tommy
AU - Mazza, Stefano
AU - Zavaglia, Claudio
AU - Sanduzzi-Zamparelli, Marco
AU - Fraile-López, Miguel
AU - Czauderna, Carolin
AU - Di Costanzo, Giovanni
AU - Bhoori, Sherrie
AU - Pinter, Matthias
AU - Manini, Matteo Angelo
AU - Amaddeo, Giuliana
AU - Yunquera, Ainhoa Fernandez
AU - Piñero, Federico
AU - Blanco Rodríguez, Maria Jose
AU - Anders, Margarita
AU - Aballay Soteras, Gabriel
AU - Villadsen, Gerda Elisabeth
AU - Yoon, Peter Daechul
AU - Cesarini, Lucia
AU - Díaz-González, Álvaro
AU - González-Diéguez, Maria Luisa
AU - Tortora, Raffaella
AU - Weinmann, Arndt
AU - Mazzaferro, Vincenzo
AU - Romero Cristóbal, Mario
AU - Crespo, Gonzalo
AU - Regnault, Helene
AU - De Giorgio, Massimo
AU - Varela, Maria
AU - Prince, Rebecca
AU - Scudeller, Luigia
AU - Donato, Maria Francesca
AU - Wörns, Marcus Alexander
AU - Bruix, Jordi
AU - Sapisochin, Gonzalo
AU - Lampertico, Pietro
AU - Reig, Maria
PY - 2021/12
Y1 - 2021/12
N2 - Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared with best supportive care (BSC) in LT patients after sorafenib discontinuation. This observational multicenter retrospective study included LT patients with HCC recurrence who discontinued first-line sorafenib. Group 1 comprised regorafenib-treated patients, whereas the control group was selected among patients treated with BSC due to unavailability of second-line options at the time of sorafenib discontinuation and who were sorafenib-tolerant progressors (group 2). Primary endpoint was overall survival (OS) of group 1 compared with group 2. Secondary endpoints were safety and OS of sequential treatment with sorafenib + regorafenib/BSC. Among 132 LT patients who discontinued sorafenib included in the study, 81 were sorafenib tolerant: 36 received regorafenib (group 1) and 45 (group 2) received BSC. Overall, 24 (67%) patients died in group 1 and 40 (89%) in group 2: the median OS was significantly longer in group 1 than in group 2 (13.1 versus 5.5 months; P < 0.01). Regorafenib treatment was an independent predictor of reduced mortality (hazard ratio, 0.37; 95% confidence interval [CI], 0.16-0.89; P = 0.02). Median treatment duration with regorafenib was 7.0 (95% CI, 5.5-8.5) months; regorafenib dose was reduced in 22 (61%) patients for adverse events and discontinued for tumor progression in 93% (n = 28). The median OS calculated from sorafenib start was 28.8 months (95% CI, 17.6-40.1) in group 1 versus 15.3 months (95% CI, 8.8-21.7) in group 2 (P < 0.01). Regorafenib is an effective second-line treatment after sorafenib in patients with HCC recurrence after LT.
AB - Safety of regorafenib in hepatocellular carcinoma (HCC) recurrence after liver transplantation (LT) has been recently demonstrated. We aimed to assess the survival benefit of regorafenib compared with best supportive care (BSC) in LT patients after sorafenib discontinuation. This observational multicenter retrospective study included LT patients with HCC recurrence who discontinued first-line sorafenib. Group 1 comprised regorafenib-treated patients, whereas the control group was selected among patients treated with BSC due to unavailability of second-line options at the time of sorafenib discontinuation and who were sorafenib-tolerant progressors (group 2). Primary endpoint was overall survival (OS) of group 1 compared with group 2. Secondary endpoints were safety and OS of sequential treatment with sorafenib + regorafenib/BSC. Among 132 LT patients who discontinued sorafenib included in the study, 81 were sorafenib tolerant: 36 received regorafenib (group 1) and 45 (group 2) received BSC. Overall, 24 (67%) patients died in group 1 and 40 (89%) in group 2: the median OS was significantly longer in group 1 than in group 2 (13.1 versus 5.5 months; P < 0.01). Regorafenib treatment was an independent predictor of reduced mortality (hazard ratio, 0.37; 95% confidence interval [CI], 0.16-0.89; P = 0.02). Median treatment duration with regorafenib was 7.0 (95% CI, 5.5-8.5) months; regorafenib dose was reduced in 22 (61%) patients for adverse events and discontinued for tumor progression in 93% (n = 28). The median OS calculated from sorafenib start was 28.8 months (95% CI, 17.6-40.1) in group 1 versus 15.3 months (95% CI, 8.8-21.7) in group 2 (P < 0.01). Regorafenib is an effective second-line treatment after sorafenib in patients with HCC recurrence after LT.
UR - http://www.scopus.com/inward/record.url?scp=85114912138&partnerID=8YFLogxK
U2 - 10.1002/lt.26264
DO - 10.1002/lt.26264
M3 - Journal article
C2 - 34388851
AN - SCOPUS:85114912138
VL - 27
SP - 1767
EP - 1778
JO - Liver Transplantation
JF - Liver Transplantation
SN - 1527-6465
IS - 12
ER -